The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers

British Journal of Cancer

Volumn 98, Issue 6, 2008, Pages 1068-1075

  Goto, T ^a   Takano, M ^b   Hirata, J ^b   Tsuda, H ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Drug resistance; FOXO1; Ovarian cancer; Paclitaxel; Reactive oxygen spices (ROS)

Indexed keywords

CARBOPLATIN; MANGANESE SUPEROXIDE DISMUTASE; PACLITAXEL; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR FKHR;

ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; WESTERN BLOTTING;

CELL DEATH; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MNSS BLOOD-GROUP SYSTEM; OVARIAN NEOPLASMS; PACLITAXEL; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE;

EID: 40849097782     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604279     Document Type: Article

References (31)

1. Bacus SS, Gudkov AV, Lowe M, Lvass L, Yung Y, Komarov AP, Kevomarsi K, Yarden Y, Seger R (2001) Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 20: 147-155
2. Baird RD, Kaye SB (2003) Drug resistance reversal - are we getting closer? Eur J Cancer 39: 2450-2461
3. Benhar M, Dalyot I, Engelberg D, Levitzki A (2001) Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol Cell Biol 21: 6913-6926
4. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868
5. Burdon RH (1995) Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med 18: 775-794
6. Davis Jr W, Ronai Z, Tew KD (2001) Cellular thiols and reactive oxygen species in drug-induced apoptosis. J Pharmacol Exp 296: 1-6
7. Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NS, Lam EW, Burgering BM, Raaijmaters JA, Lammers JW, Koenderman L, Coffer PJ (2000) Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol Cell Biol 20: 9138-9148
8. Duan Z, Feller AJ, Person RT, Chabner BA, Seiden MU (1999) Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA microarray technology: Analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 5: 3445-3453
9. Goto T, Takano M, Albergaria A, Briese J, Pomeranz KM, Cloke B, Fusi L, Feroze-Zaidi F, Maywald N, Sajin M, Dina RE, Ishihara O, Takeda S, Lam EW, Bamberger AM, Ghaem-Maghami S, Brosens JJ (2008) Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells. Oncogene 27(1): 9-19
10. Goto T, Takano M, Sakamoto M, Kondo A, Hirata J, Kita T, Tsuda H, Tenjin Y, Kikuchi Y (2006) Gene expression profiles with cDNA microarray reveals RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers. Oncol Rep 15: 1265-1271
11. Kajihara T, Jones M, Fusi L, Takano M, Feroze-Zaidi F, Pirianov G, Mehmet H, Ishihara O, Higham JM, Lam EW, Brosens JJ (2006) Differential expression of FOXO1 and FOXO3a confers resistance to oxidative cell death upon endometrial decidualization. Mol Endocrinol 20: 2444-2455
12. Kikuchi Y, Miyauchi M, Kizawa I, Oomori K, Katoh K (1986) Establishment of a cisplatin-resistant human ovarian cancer cell line. J Natl Cancer Inst 77: 1181-1185
13. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, Huang TT, Bos JL, Medema RH, Burgering BM (2002) Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419: 316-321
14. Kops GJ, de Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL, Burgering BM (1999) Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 398: 630-634
15. Masanek U, Stammler G, Volm M (1997) Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin. Anticancer Drugs 8: 189-198
16. Matsumoto M, Han S, Kitamura T, Accili D (2006) Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest 116: 2464-2472
17. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Patridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6
18. Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti FO, Ferrandina G, Scambia G (2005) Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 11: 298-305
19. Nemoto S, Fergusson MM, Finkel T (2004) Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science 306: 2105-2108
20. Penson RT, Oliva E, Skates SJ, Glyptis T, Fuller Jr AF, Goodman A, Seiden MV (2004) Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 93: 98-106
21. Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ, Pu YS (2005) Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 65: 8455-8460
22. Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332: 1004-1014
23. Sunters A, Fernandez de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, Saunders CA, Coffer PJ, Medema RH, Coombes RC, Lam EW (2003) FOXO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem 278: 49795-49805
24. Szatrowski TP, Nathan CF (1991) Production of large amounts of hydrogen peroxide by human tumour cells. Cancer Res 51: 794-798
25. Tobiume K, Matsuzawa A, Takahashi T, Nishitoh H, Morita K, Takeda K, Minowa O, Miyazono K, Noda T, Ichijo H (2001) ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep 2: 222-228
26. Varbiro G, Veres B, Gallyas F, Sumeqi B (2001) Direct effect of Taxol on free radical formation and mitochondrial permeability transition. Free Radic Biol Med 31: 548-558
27. Vasey PA (2003) Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br J Cancer 89: S23-S28
28. Wiseman LR, Spencer CM (1998) Paclitaxel: An update of its use in the treatment of metastatic breast and ovarian and other gynecological cancers. Drugs Aging 12: 305-334
29. Yamamoto K, Kikuchi Y, Kudoh K, Hirata J, Kita T, Nagata I (2000a) Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selected for cisplatin-resistant ovarian carcinoma. Jpn J Clin Oncol 30: 446-449
30. Yamamoto K, Kikuchi Y, Kudoh K, Nagata I (2000b) Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. J Cancer Res Clin Oncol 126: 168-172
31. Yokoyama Y, Sato S, Fukushi Y, Sakamoto T, Futagami M, Saito Y (1999) Significance of multi-drug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer. J Obstet Gynaecol Res 25: 387-3894